2025-01-31 - Analysis Report
## Merck & Co Inc (MRK) Stock Review

**1. Performance Comparison and Divergence:**

Merck & Co Inc (MRK), a leading pharmaceutical company, has shown a cumulative return of 63.36% over the analyzed period.  This lags significantly behind the S&P 500 (VOO), which achieved a cumulative return of 121.09%. The difference is -57.7%, placing it at the 5.9th percentile of its historical range of divergence against the S&P 500.  This indicates MRK underperformed the broader market during this period.

**Alpha and Beta Analysis:**

The provided data reveals inconsistent performance relative to the market (as indicated by the negative alpha consistently around -0.1)  while showing a high beta.  This suggests that MRK's returns are highly sensitive to market movements, but it has consistently underperformed the market in the given periods.  The market capitalization (Cap(B)) shows consistent growth over the years.


**2. Recent Price Movement:**

* **Closing Price:** $98.95
* **5-Day Moving Average:** $97.63
* **20-Day Moving Average:** $98.68
* **60-Day Moving Average:** $99.34

The price is slightly above the 5-day and 20-day moving averages, suggesting recent upward momentum. However, it's below the 60-day moving average, indicating a potential short-term trend reversal. The recent price increase of $0.68 from the previous close represents a minor, positive change.


**3. Technical Indicators and Expected Return:**

* **RSI:** 47.21 – Suggests the stock is nearing oversold territory, but not yet definitively so.
* **PPO:** 0.05 – A slightly positive PPO suggests bullish momentum, though it is weak.
* **20-Day Relative Divergence Change:** +5.5 – Indicates a recent short-term upward trend.

The  high expected return of 109.5% over the long term (2+ years) suggests a significant potential for outperformance relative to the S&P 500, even though the current short term performance has been relatively weak. However, this projection should be treated with caution.


**4. Recent Earnings Analysis:**

The provided earnings data is inconsistent, showing variations in EPS and revenue across quarters.  There is a duplicate entry for 2024-11-06.  A more detailed analysis requires consistent and accurate data across the reporting periods.  More data is needed for a robust trend analysis.

**5. Financial Information:**

**Revenue and Profitability:** Revenue shows relatively stable growth, though there's a slight dip in the last quarter of 2023. Profit margins are generally high and consistent, indicating strong profitability.

**Capital and Profitability:**  Equity has generally increased, and Return on Equity (ROE) fluctuates but is mostly positive.  The negative ROE in Q4 2023 needs further investigation to determine the cause.  Consistent and positive ROE is a key indicator of financial health.


**7. Overall Analysis:**

Merck shows high profitability and generally stable revenue growth.  However, its stock price performance has lagged the S&P 500 considerably over the analyzed period.  While long-term projections indicate potential for significant outperformance, the recent performance shows mixed signals.  The inconsistent earnings data and the need for clarifying the Q4 2023 ROE result makes further, more in-depth analysis necessary before drawing definitive conclusions about investment strategy.  Technical indicators suggest a potential upward trend, but it is not conclusive.

**8. Disclaimer:** This analysis is based on the limited data provided.  It is not financial advice and should not be used as the sole basis for investment decisions.  Conduct thorough due diligence and consider consulting with a financial advisor before making any investment choices.
